Two Sigma Investments LP Acquires New Stake in Schrödinger, Inc. (NASDAQ:SDGR)

Two Sigma Investments LP bought a new position in shares of Schrödinger, Inc. (NASDAQ:SDGR) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 100,494 shares of the company’s stock, valued at approximately $1,939,000. Two Sigma Investments LP owned approximately 0.14% of Schrödinger at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC grew its holdings in shares of Schrödinger by 421.6% during the third quarter. Barclays PLC now owns 107,554 shares of the company’s stock worth $1,995,000 after buying an additional 86,933 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Schrödinger in the fourth quarter valued at approximately $325,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Schrödinger by 60.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock worth $67,718,000 after purchasing an additional 1,319,464 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Schrödinger in the fourth quarter worth $330,000. Finally, Amundi boosted its holdings in Schrödinger by 197.7% during the fourth quarter. Amundi now owns 26,753 shares of the company’s stock worth $544,000 after purchasing an additional 17,766 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Schrödinger

In other news, insider Karen Akinsanya sold 16,723 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $25.09, for a total value of $419,580.07. Following the transaction, the insider now directly owns 15,625 shares of the company’s stock, valued at $392,031.25. This represents a 51.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SDGR shares. Piper Sandler lowered their price target on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. KeyCorp lifted their target price on Schrödinger from $30.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $32.80.

Schrödinger Trading Up 0.9%

Shares of SDGR opened at $21.63 on Monday. The company’s fifty day simple moving average is $22.70 and its 200 day simple moving average is $22.17. Schrödinger, Inc. has a 1-year low of $16.60 and a 1-year high of $28.47. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -9.24 and a beta of 1.84.

Schrödinger (NASDAQ:SDGR) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.01). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The firm had revenue of $59.55 million for the quarter, compared to analyst estimates of $54.60 million. During the same quarter in the prior year, the firm earned ($0.86) earnings per share. The firm’s revenue for the quarter was up 62.7% on a year-over-year basis. As a group, research analysts forecast that Schrödinger, Inc. will post -2.37 earnings per share for the current year.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.